US 11,912,782 B2
BCMA monoclonal antibody-drug conjugate
Krista Kinneer, Gaithersburg, MD (US); Reena Varkey, Gaithersburg, MD (US); Xiaodong Xiao, Frederick, MD (US); Elaine M. Hurt, Gaithersburg, MD (US); and David Tice, Gaithersburg, MD (US)
Assigned to MedImmune, LLC, Gaithersburg, MD (US)
Filed by MedImmune, LLC, Gaithersburg, MD (US)
Filed on Mar. 29, 2021, as Appl. No. 17/215,479.
Application 17/215,479 is a division of application No. 16/050,944, filed on Jul. 31, 2018, granted, now 10,988,546.
Claims priority of provisional application 62/596,194, filed on Dec. 8, 2017.
Claims priority of provisional application 62/539,825, filed on Aug. 1, 2017.
Prior Publication US 2021/0214460 A1, Jul. 15, 2021
Int. Cl. C07K 16/30 (2006.01); C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); A61K 31/202 (2006.01); A61K 31/4741 (2006.01); A61K 31/551 (2006.01); A61K 31/7048 (2006.01); C12N 15/62 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/3061 (2013.01) [A61K 31/202 (2013.01); A61K 31/4741 (2013.01); A61K 31/551 (2013.01); A61K 31/7048 (2013.01); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); A61K 47/6867 (2017.08); A61P 35/00 (2018.01); C07K 16/2878 (2013.01); C12N 15/62 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] 19 Claims
 
1. A method of killing multiple myeloma cells comprising:
contacting multiple myeloma cells that express B-cell maturation antigen (BCMA) with an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against BCMA conjugated to a cytotoxin, wherein the monoclonal antibody comprises
(a) a heavy chain variable region comprising a complementarity determining region 1 (HCDR1) amino acid sequence of SEQ ID NO: 1, an HCDR2 amino acid sequence of SEQ ID NO: 2, and an HCDR3 amino acid sequence of SEQ ID NO: 3; and
(b) a light chain variable region comprising a complementarity determining region 1 (LCDR1) amino acid sequence of SEQ ID NO: 4, an LCDR2 amino acid sequence of SEQ ID NO: 5, and an LCDR3 amino acid sequence of SEQ ID NO: 6;
wherein the ADC binds to BCMA on the multiple myeloma cells and kills the multiple myeloma cells.